Palisade Bio (PALI) Stock Price, News & Analysis

Company Overview

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and complications associated with gastrointestinal surgery. The company’s research is centered on treatments designed to address intestinal inflammation, impaired barrier function and other factors that can delay recovery following surgery.

Palisade Bio’s lead product candidate is LB1148, an orally administered, locally acting serine protease inhibitor. The company has evaluated LB1148 for postoperative ileus, a temporary disruption of intestinal movement that can occur after abdominal surgery, as well as for other gastrointestinal conditions and surgery-related complications.

Palisade Bio is headquartered in San Diego, California, and has advanced LB1148 through clinical development. The company’s programs remain focused on translating its understanding of gastrointestinal inflammation and intestinal barrier function into potential therapies for patients with limited treatment options.

Key Stats

• Today's Range: $1.47 to $1.57
• 50-Day Range: $1.35 to $2.20
• 52-Week Range: $1.32 to $2.86
• Volume: 1.84 million shs
• Average Volume: 3.83 million shs
• Market Capitalization: $268.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.29
• Consensus Rating: Buy

Palisade Bio Stock Analysis - MarketRank™

Palisade Bio scored higher than 65% of companies evaluated by MarketBeat, and ranked 319th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Palisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Palisade Bio has a consensus price target of $9.29, representing about 503.0% upside from its current price of $1.54.

Amount of Analyst Coverage

Palisade Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Palisade Bio are expected to decrease in the coming year, from ($0.23) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Palisade Bio is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palisade Bio is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Palisade Bio has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.81% of the float of Palisade Bio has been sold short.

Short Interest Ratio / Days to Cover

Palisade Bio has a short interest ratio ("days to cover") of 6.06.

Change versus previous month

Short interest in Palisade Bio has recently increased by 2.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palisade Bio does not currently pay a dividend.

Dividend Growth

Palisade Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.34

News Sentiment

Palisade Bio has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Palisade Bio this week, compared to 3 articles on an average week.

Search Interest

11 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.

MarketBeat Follows

8 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $49,000.00 in company stock, which represents 0.0183% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Palisade Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.07% of the stock of Palisade Bio is held by insiders.

Percentage Held by Institutions

11.79% of the stock of Palisade Bio is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PALI
• CIK: 1357459
• Web: www.palisadebio.com
• Phone: (858) 704-4900
• Fax: N/A
• Employees: 14
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Palisade Bio: $9.29
• High Price Target: $25.00
• Low Price Target: $5.00
• Potential Upside/Downside: +503.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.78 million
• Net Margins: N/A
• Pretax Margin: -6,388.20%
• Return on Equity: -33.47%
• Return on Assets: -31.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.26
• Quick Ratio: 24.26

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 1,073.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.87 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 174,270,000
• Free Float: 174,149,000
• Market Cap: $268.38 million
• Optionable: Not Optionable
• Beta: 1.61